PND‐1186 is a potent FAK inhibitor with good oral bioavailability28 and it has been shown to inhibit tumor growth and metastasis in pre‐clinical models.29 We tested IC50 against PND‐1186 in HCC3‐4 and HCC4‐4 mouse c‐Myc HCC cell lines as well as two randomly selected human HCC cell lines, SNU475 and SNU398 cells using cell viability assays. Here, PTK2 is linked to hepatocellular carcinoma.